angioplasty

drug elutin baloon_reestenosis_instrastent

Efficacy of Micromesh-Covered Stents in Carotid Artery Stenting

Most literature, old and recent, associates carotid artery stenting with a higher rate of stroke (although minor) when compared with carotid endarterectomy during the acute period. However, 30-day outcomes of angioplasty and surgery are comparable. Many technical advancements, including new stent designs and different cerebral protection mechanisms, have improved the outcomes of angioplasty in clinical<a href="https://solaci.org/en/2017/11/10/efficacy-of-micromesh-covered-stents-in-carotid-artery-stenting/" title="Read more" >...</a>

ARTE: ¿AsEl fin de la aspirina para los pacientes anticoagulados que reciben angioplastiapirina o aspirina más clopidogrel post TAVI?

The End of Aspirin for Anticoagulated Patients Undergoing PCI

The discussion about the best anti-thrombotic strategy for patients with&nbsp;atrial fibrillation&nbsp;undergoing PCI seemed never-ending until the RE-DUAL PCI trial was published in the New England Journal of Medicine (NEJM). This study has arrived to simplify the tough choice between the risk of a thrombotic event vs. the risk of bleeding with a simpler scheme, without<a href="https://solaci.org/en/2017/11/08/the-end-of-aspirin-for-anticoagulated-patients-undergoing-pci/" title="Read more" >...</a>

TCT 2017 | SENIOR: DES con polímero reabsorbible y tiempo de doble antiagregación corto en pacientes añosos

TCT 2017 | SENIOR: DES with a Bioresorbable Polymer and Short Dual Antiplatelet Therapy in Elderly Patients

&nbsp;Courtesy of the SBHCI. This study sought to assess the safety and efficacy of an everolimus-eluting stent with a biodegradable polymer (SYNERGY&nbsp;II) vs. a conventional stent (REBEL) in patients &gt;75&nbsp;years old with short duration of dual antiplatelet therapy. Before randomization, investigators recorded the planned duration of dual antiplatelet therapy (1&nbsp;month for stable patients and 6&nbsp;months<a href="https://solaci.org/en/2017/11/03/tct-2017-senior-des-with-a-bioresorbable-polymer-and-short-dual-antiplatelet-therapy-in-elderly-patients/" title="Read more" >...</a>

DKCRUSH-V: lo más simple no siempre es lo mejor en el tronco de la coronaria izquierda

DKCRUSH-V: What Is Simple Is Not Always Best for the Left Main Coronary Artery

Courtesy of the SBHCI. Angioplasty of true distal left main bifurcation lesions with a double-kissing (DK) crush two-stent strategy, compared with provisional stenting, results in lower rates of target lesion failure at 1&nbsp;year. These findings were largely driven by lower rates of target vessel infarction and definite/probable stent thrombosis. Read also: &#8220;EXCEL-QOL Substudy: Similar Quality<a href="https://solaci.org/en/2017/11/01/dkcrush-v-what-is-simple-is-not-always-best-for-the-left-main-coronary-artery/" title="Read more" >...</a>

CULPRIT-SHOCK Results Will Transform Guidelines and Clinical Practice

&nbsp;Courtesy of the SBHCI. After treating the culprit lesion in patients with acute myocardial infarction complicated by cardiogenic shock, continuing revascularization of all other lesions worsens outcomes. This finding of the CULPRIT-SHOCK trial has changed entirely the way we treated this patient group and will surely modify guidelines. Culprit-lesion treatment with the option to perform<a href="https://solaci.org/en/2017/11/01/culprit-shock-results-will-transform-guidelines-and-clinical-practice/" title="Read more" >...</a>

DARE: los balones farmacológicos compiten con los DES para tratar la reestenosis intrastent

DARE: Drug-Coated Balloons Compete with DES for the Treatment of In-Stent Restenosis

Courtesy of the Brazilian Society of Hemodynamics and Interventional Cardiology (SBHCI). The SeQuent Please paclitaxel-coated balloon provides non-inferior angiographic results when compared with the Xience everolimus-eluting stent for the treatment of in-stent restenosis. At 6&nbsp;months, the minimal lumen diameter was 1.71&nbsp;mm in the drug-coated balloon arm and 1.74&nbsp;mm in the Xience arm, a difference that<a href="https://solaci.org/en/2017/11/01/dare-drug-coated-balloons-compete-with-des-for-the-treatment-of-in-stent-restenosis/" title="Read more" >...</a>

DES de 2.0 mm para vasos muy pequeños: ¿Es viable?

2.0-mm DES for Very Small Vessels: Are They Viable?

The reference vessel diameter is a fundamental factor for restenosis after coronary angioplasty even with drug-eluting stents. The smallest sized stents available are 2.25&nbsp;mm in diameter, but even smaller vessels can be symptomatic. This was a prospective multicenter trial of the Resolute Onyx 2.0-mm zotarolimus-eluting stent.&nbsp;The primary endpoint was target lesion failure. Read also: &#8220;Effects<a href="https://solaci.org/en/2017/10/25/2-0-mm-des-for-very-small-vessels-are-they-viable/" title="Read more" >...</a>

balon farmacologico

Excellent Outcomes for the First Sirolimus Eluting Balloon Tested on Instent Restesosis

Much has been done since studies on conventional balloon angioplasty&nbsp;for BMS&nbsp;instent restenosis showed over 40% new revascularization.&nbsp; Drug eluting stents, aimed at improving this problem, have never achieved 0% restenosis, which is why technologies such as&nbsp;paclitaxel&nbsp;coated balloons have been developed, with reasonable efficacy (8% to 10% reinterventions rate for BMS restenosis and 17% to 23%<a href="https://solaci.org/en/2017/10/20/excellent-outcomes-for-the-first-sirolimus-eluting-balloon-tested-on-instent-restesosis/" title="Read more" >...</a>

Las plataformas bioabsorbibles no deben ser elegidas por sobre los DES actuales

Bioresorbable Scaffolds Must Not Be Chosen Over Current DES

Although there are 4 approved bioresorbable scaffolds (BRS) in Europe, experts suggest that current drug-eluting stents (DES) are the best option for coronary angioplasty. These new guidelines jointly published by the European Society of Cardiology (ESC) and the Association of Percutaneous Cardiovascular Interventions (EAPCI) are an update on the use of BRS in clinical practice<a href="https://solaci.org/en/2017/10/19/bioresorbable-scaffolds-must-not-be-chosen-over-current-des/" title="Read more" >...</a>

La coronariografía precoz reduce la mortalidad en SCA sin supradesnivel del ST de alto riesgo

Early Coronary Angiography in High-Risk Non-ST-Elevation ACS

Coronary angiography is essential for patients admitted with non-ST-elevation acute coronary syndrome, since it allows physicians to confirm the diagnosis, stratify the risk, and define the revascularization and antithrombotic management strategies. &nbsp; There is no doubt that these patients should be studied invasively, but the timing for that is still uncertain. &nbsp; Coronary catheterization within<a href="https://solaci.org/en/2017/10/09/early-coronary-angiography-in-high-risk-non-st-elevation-acs/" title="Read more" >...</a>

Top